πŸ‡ΊπŸ‡Έ FDA
Patent

US 10307481

CD37 immunotherapeutics and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10307481 (CD37 immunotherapeutics and uses thereof) held by Aptevo Research and Development LLC expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aptevo Research and Development LLC
Grant date
Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K39/3955